Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
GLOBETECH PUBLISHING
FOCUS DIAGNOSTICS, INC.

Molecular Assay Detects Norovirus in Fecal Specimens

By Labmedica International staff writers
Posted on 09 Jan 2014
Image: The AccuPower Norovirus Real-time RT-PCR assay kit (Photo courtesy of Bioneer Corporation).
Image: The AccuPower Norovirus Real-time RT-PCR assay kit (Photo courtesy of Bioneer Corporation).
A new real-time reverse transcription polymerase chain reaction (RT-PCR) assay has been evaluated in for the detection of human Norovirus in stool specimens.

Noroviruses are a genetically diverse group of single-stranded ribonucleic acid (RNA), nonenveloped viruses in the Caliciviridae family and are classified into five genogroups by phylogenetic analysis of the capsid protein, of which genogroups II (GII), I (GI), and IV (GIV) are responsible for human outbreak.

Scientists at the Hallym University College of Medicine (Seoul, South Korea) analyzed 281 fecal suspensions (10% to 20% fecal specimen diluted with saline) collected and stored at -70 °C between August 2010 and April 2011. These comprised 109 Norovirus-positive and 172 Norovirus-negative stool samples, as determined using a Norovirus enzyme-linked immunosorbent assay (ELISA).

RNA was extracted from fecal suspensions and prepared using the QIAamp Viral RNA Mini Kit (Qiagen; Hilden, Germany) and the Qiagen QIAcube platform. The AccuPower Norovirus Real-time RT-PCR assay (Bioneer Corporation; Daejeon, South Korea) and the RIDAGENE Norovirus V assay (R-Biopharm, Darmstadt, Germany) were compared as Norovirus assays. Norovirus positivity and genotype were confirmed by direct sequencing.

Of the 109 Norovirus-positive samples by ELISA, 91 (83.5%) were positive by both PCR kits, and two (1.8%) were positive only by the AccuPower kit, whereas 16 cases (14.7%) were negative by both PCR kits. Of the 172 Norovirus-negative samples by ELISA, 159 (92.4%) were negative, and five (2.9%) were positive by both PCR kits, one (0.6%) was positive by the RIDAGENE kit, and seven (4.1%) were positive by the AccuPower kit. The lowest mean numbers of genome copies of GI and GII that could be detected by the AccuPower assay were 12.3 and 5.6 RNA copies/reaction, respectively.

The authors concluded that the AccuPower Norovirus Real-time RT-PCR Kit showed good analytical and clinical performance, including excellent analytical sensitivity and reproducibility, without cross-reactivity and they recommend this assay system as an efficient diagnostic tool for Norovirus infection. Noroviruses are responsible for an estimated 218,000 deaths each year among children younger than five years in developing countries and 1.1 million hospitalizations worldwide. The study was published in the January 2014 edition of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Hallym University College of Medicine
Qiagen
Bioneer Corporation 




Sekisui Diagnostics
EUROIMMUN AG
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.